Lutetium-177 DOTATATE: A Practical Review
Review on Lutetium-177 dotatate in Neuroendocrine tumours, in Practical radiation oncology (2022), one of the most cited Europe PMC records with Lutetium-177 dotatate in its title.
Overview
Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that originate in endocrine tissues throughout the body. Though most are indolent, clinical outcomes vary greatly based on histologic differentiation and grade. Peptide receptor radionuclide therapy has emerged as a promising treatment for patients with locally advanced and/or metastatic disease refractory to standard of care treatment. The phase III NETTER-1 trial found that [ 177 Lu] Lu-DOTA-[Tyr 3 ]-octreotate improved disease-free survival versus octreotide alone for somatostatin receptor-positive gastroenteropancreatic NETs and had a favorable toxicity profile, leading to Food and Drug Administration approval. [ 177 Lu] Lu-DOTA-[Tyr 3 ]-octreotate is an important new treatment that expands the role of radiation in the treatment of NETs. Several important trials are ongoing to better elucidate the role of this treatment.
Indexed on Europe PMC as PubMed record 35717045 (DOI 10.1016/j.prro.2022.02.002). Its title names Lutetium-177 dotatate and its text names Neuroendocrine tumours; PubMed types it as a review (Review). It was matched automatically to the idea "Dosimetry-personalised PRRT instead of four fixed cycles" and no figure has been checked by an editor.
One of the most cited reviews Europe PMC returns for Lutetium-177 dotatate in Neuroendocrine tumours, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
- Matched by Lutetium-177 dotatate in the title and Neuroendocrine tumours in the title or abstract of the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.
- A review summarises other studies; the primary reports it cites are the evidence.